RSRuxandra Teodora Stan

Ruxandra Teodora Stan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ruxandra Teodora Stan has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Drivers of Migration Readiness Among Romanian Pharmacy Students: An Extended Push–Pull–Mooring Model

    by Pompei Mititean, Alin-Viorel FocșA, Maria Drăgan, Magdalena Bîrsan, Maria-Manuela Apostol, Ruxandra-Teodora Stan, Adina-Andreea Balea, Ioana-Cezara Caba, Cătălina Daniela Stan

    Background/Objectives: The potential migration of future pharmacists can affect healthcare systems’ ability to maintain a sufficient, stable, and adequately distributed workforce, with implications for the continuity of pharmaceutical services and the safe use of medicines. This study examines Migration Readiness (MR) among pharmacy students in Romania as a candidate aggregate indicator of future workforce-retention vulnerability and identifies the associated professional, economic, social, and structural factors. Methods: A quantitative, cross-sectional, and observational design was employed, based on 520 valid questionnaires. An extended Push–Pull–Mooring model was developed and tested, incorporating internal professional pressures (PUSH), professional prospects in Romania (DPO), the professional-economic appeal of external opportunities (PEP), the appeal associated with quality of life (QLP), personal and social barriers (PB), structural barriers (SB), and Migration Readiness (MR). The model was estimated using PLS-SEM in SmartPLS 4. The significance of relationships was assessed via bootstrapping with 10,000 subsamples, while predictive performance was evaluated using PLSpredict and CVPAT. Results: The model explains 39.2% of the variance in MR and demonstrates a good approximate fit (estimated SRMR = 0.038). PUSH is negatively associated with DPO (β = −0.387) and positively associated with PEP (β = 0.413) and QLP (β = 0.173). PEP is strongly associated with QLP (β = 0.523), while PEP and QLP are positively associated with MR (β = 0.272 and β = 0.221, respectively). DPO, PB and SB are negatively associated with MR (β = −0.128, β = −0.187 and β = −0.175, respectively). Significant specific indirect associations indicate that part of the association between professional pressures and MR operates through the assessment of domestic career prospects and external opportunities. Conclusions: Pharmacy students’ migration readiness reflects a multidimensional process in which internal professional conditions, the attractiveness of external opportunities, and mobility barriers act simultaneously. At an aggregate level, MR may represent a candidate perceptual indicator of future workforce-retention vulnerability; however, longitudinal validation against actual post-graduation employment and migration outcomes is required before operational workforce use. The results suggest that pharmaceutical workforce planning should combine measures addressing career prospects, working conditions, professional development, and quality of life, rather than focusing solely on remuneration.

  • Open Access

    Artificial Intelligence, Microrobots/Nanorobots and Pharmaceutically Optimized Nanocarrier Systems for Precision Tumor Multitargeting

    by Laura Marinela Ailioaie, Constantin Ailioaie, Ruxandra Teodora Stan, Dragos Andrei Chiran

    Precision oncology increasingly requires multi-target strategies addressing tumor heterogeneity, microenvironmental barriers, immune evasion, and drug resistance. This narrative review critically examines the convergence of artificial intelligence (AI), microrobotic/nanorobotic systems, and pharmaceutically optimized nanocarriers for precision tumor multi-targeting. It highlights emerging intelligent nanomedicine strategies while distinguishing clinical evidence for selected nanocarrier products from preclinical and conceptual integration. This review explores AI-guided formulation design and patient stratification; microrobots and nano/micromotors for active delivery and intratumoral penetration; and optimized, stimuli-responsive nanocarriers for co-delivery of chemotherapeutics, immunomodulators, nucleic acids, and gene-editing agents. Tumor multi-targeting, microenvironment-responsive release, and synchronized drug delivery are critically assessed. AI-guided formulation studies include computational prediction and prospective laboratory validation, whereas active delivery platforms have predominantly been evaluated in vitro and in animal models. Preclinical and conceptual findings suggest that integrating AI-guided design, active navigation, and responsive nanocarriers may enhance spatial and temporal delivery control; reductions in systemic toxicity require system-specific validation. Study-specific quantitative matrices compare model validation, actuation conditions, payloads, release characteristics, and exposure measures, explicitly identifying missing data and non-comparable endpoints. Target prioritization incorporates biological validity, druggability, delivery feasibility, and clinical actionability. Investigational digital twins require longitudinal data quality control, calibrated uncertainty, drift surveillance, and clinician oversight. Although selected robotic–carrier combinations demonstrate preclinical benefits, fully integrated platforms enabling patient-specific adaptive treatment lack clinical validation. Translation requires indication-specific comparisons with simpler formulations, reproducible manufacturing, validated navigation, and prospective benefit–risk assessment. Future research should prioritize pharmaco-nanotechnologies, refined cancer molecular classification, and clinician-governed decision support before adaptive AI-assisted multi-target nanomedicine.

  • Open Access

    Exploring Romanian Pharmacists’ Migration Readiness Through the Push–Pull–Mooring Framework: A PLS-SEM Study

    by Alin-Viorel FocșA, Ionuț-Iulian Lungu, Maria Drăgan, Magdalena Bîrsan, Ioana-Cezara Caba, Ruxandra-Teodora Stan, Maria-Manuela Apostol, Pompei Mititean, Cătălina Daniela Stan

    Background: The international migration of pharmaceutical professionals has implications for the availability of human resources and the sustainability of pharmaceutical services; however, the determinants of pharmacists’ readiness for cross-border mobility remain insufficiently examined. This study examines the associations of professional factors, the importance assigned to migration-related benefits, and relocation-related barriers with Migration Readiness within the Push–Pull–Mooring (PPM) theoretical framework. Methods: Data were collected via an online questionnaire administered to a sample of 542 professionally active pharmacists in Romania and were analyzed using Partial Least Squares Structural Equation Modeling (PLS-SEM) with SmartPLS 4. The findings indicate that dissatisfaction with working conditions and remuneration is positively associated with both the Importance of Migration Benefits and Migration Readiness. Greater importance assigned to potential economic, professional, and personal migration-related benefits is, in turn, positively associated with Migration Readiness. Results: Among the mooring factors, Migration Mooring Barriers exhibit the strongest direct association with Migration Readiness, with a negative direction of the relationship; within this construct, family responsibilities and uncertainty regarding adjustment displayed the largest positive relative weights within the formative composite. By contrast, perceived institutional and professional deficits do not display significant associations with either perceived migration benefits or readiness to migrate. In addition, the internal cross-validated predictive assessment yielded positive Q2 predict values for both endogenous constructs (Importance of Migration Benefits, IMB = 0.210; Migration Readiness, MR = 0.193). CVPAT indicated significantly lower predictive loss for the PLS-SEM model than for the indicator-mean and linear-model benchmarks, although the predictive advantage over the linear model was modest. These results support the internal predictive performance of the selected model for questionnaire responses within the analyzed sample. They do not establish the model’s ability to predict subsequent migration or monitor workforce vulnerability over time. The model should therefore be regarded as a candidate framework for future longitudinal and externally validated workforce research. Conclusions: The findings provide exploratory support for examining pharmacists’ Migration Readiness within the PPM framework. Because the instrument was author-developed or conceptually adapted from previous literature, measurement evaluation and refinement and structural-model testing were conducted within the same convenience sample, and the convergent validity of the formative composites was not established through redundancy analysis, the results require independent replication. The model should not be regarded as a validated workforce-monitoring, individual-prediction, or decision-support instrument.


  • Open Access

    Biological Profile of Ferulic Acid-Based Thiazolidin-4-One Derivatives: Toxicity, Inflammation, and Oxidative Stress Biomarkers

    by Maria Dragan, Andreea-Teodora Iacob, Cornelia Mircea, Catalina Daniela Stan, Oana-Maria Dragostin, Alin-Viorel FocșA, Diana Tatarciuc, Ruxandra-Teodora Stan, Mihaela Poroch, Lenuta Profire

    Since inflammation is a fundamental process involved in tissue injury and repair, the evaluation of the anti-inflammatory potential of novel compounds is of considerable importance. Acute toxicity evaluation in Swiss albino mice revealed that the synthesized thiazolidin-4-one derivatives of ferulic acid possess moderate toxicity. The in vivo biological activity of synthesized thiazolidin-4-one derivatives (1a–j) was assessed through a model of acute inflammation induced by carrageenan in rats and in a chronic inflammation model induced in rats using the granuloma test. The compounds exhibited significant anti-inflammatory effects, with maximum activity observed 24 h after administration, suggesting a prolonged duration of action. In the acute inflammation model, compound 1g exhibited the highest anti-inflammatory activity, achieving 97.43% inhibition of inflammatory edema after 24 h. In the chronic inflammation model, all derivatives reduced granulation tissue formation, indicating inhibition of the proliferative component of inflammation, with compound 1e showing the highest inhibition (79.85%). Safety evaluation was complemented by biochemical and hematological investigations performed on blood samples collected from the experimental animals. Hepatic function was assessed by measuring serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT), together with renal and hematological parameters, revealing no significant toxicity. In addition, biochemical analysis of liver homogenates demonstrated modulation of oxidative stress markers, including malondialdehyde (MDA), superoxide dismutase (SOD), and catalase (CAT) activities, indicating that the investigated thiazolidin-4-one derivatives do not induce marked oxidative imbalance under the experimental conditions. Overall, compound 1g emerged as the most promising derivative based on its balanced anti-inflammatory efficacy and favorable oxidative stress profile.

  • Open Access

    Surface Engineering for PMMA-Based Removable Prostheses: A Narrative Review

    by Jamal Al Ashkar, Nicoleta Ioanid, Delia Teodora Dima, Ruxandra Teodora Stan, Andreas Katsonis, Ana-Maria Raluca Pauna, Roxana-Ionela Vasluianu

    Polymethylmethacrylate (PMMA) is still the most widely used prosthetic polymer, although its biological inertness and vulnerability to mechanical stress and microbiological colonization are gradually restricting its therapeutic lifespan. This narrative review develops a conceptual framework, three ceramic modifiers corresponding to three distinct biofunctional strategies, to logically guide the design of the next generation of PMMA-based prosthetic dentures. We critically analyze the transformation of hydroxyapatite (HA), silica (SiO2), and titanium dioxide (TiO2) from passive fillers to active functional phases, offering unique, complementary therapeutic advantages. Therefore, HA confers osteoconductive and bone affinity, SiO2 provides surface reactivity, tunable bioactivity, and drug release capacity, while TiO2 provides mechanical reinforcement, chemical stability, and photocatalytic antibacterial activity. These ceramics used in PMMA matrices result in hybrid materials that outperform standard resins in terms of structural, mechanical, and biological performance. Recent research on binary and ternary systems (e.g., HA–TiO2, SiO2–HA, and HA–SiO2–TiO2 in PMMA) has indicated synergistic effects, such as increased osteoblast proliferation, reduced biofilm development, improved fracture toughness, and favorable corrosion resistance in simulated oral environments. A decision matrix is also provided to assist the clinician in selecting the best ceramic for a given clinical function of a prosthetic base or provisional repair. Although polymer–ceramic hybrid systems show remarkable translational potential, there are still obstacles to be addressed in terms of long-term interfacial stability, standardized synthesis processes, and regulatory mechanisms. This review proposes a framework of PMMA as a multimodal biofunctional engineering platform rather than a basic structural polymer and provides a roadmap for the development of intelligent, interactive, and clinically durable prosthetic materials.

  • Open Access

    Beyond Carrier Design: Fabrication Method as the Hidden Driver of NSAID Nanomedicine Performance

    by Ana-Maria Raluca Pauna, Liliana Mititelu-Tartau, Angy Abu Koush, Roxana Ionela Vasluianu, Jamal Al Ashkar, Ruxandra Teodora Stan, Viorel Radu, Marius Constantin Moraru, Cosmin Gabriel Popa, Roxana Florentina Gavril, et al.

    Background/Objectives: Diclofenac (DCF) and other nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation management; however, their clinical significance is limited by poor aqueous solubility, short biological half-life, and dose-dependent gastrointestinal, renal, and cardiovascular adverse effects. Nanocarrier-based delivery systems have been extensively explored because they can enhance the apparent solubility of poorly water-soluble NSAIDs, provide controlled and sustained drug release, prolong systemic circulation, and improve drug localization at the site of action. By reducing peak plasma concentrations and off-target exposure, these systems may decrease dose-dependent gastrointestinal and systemic adverse effects while maintaining therapeutic efficacy. Most studies focus on optimizing formulation composition, while the manufacturing process is often treated as a secondary parameter. The research critically evaluates conventional and emerging fabrication methods for NSAID nanocarriers, using DCF as the principal reference compound, with emphasis on their impact on physicochemical characteristics, reproducibility, scalability, and translational potential. Methods: A structured literature search was performed in PubMed/MEDLINE, Scopus, and Web of Science (2015–2026, with emphasis on 2022–2026) for DCF and NSAID-loaded submicron delivery systems reporting quantitative formulation data and clearly defined fabrication methods, resulting in a narrative review of approximately 375–395 eligible studies, comprising 75 DCF-specific studies and approximately 300–320 studies involving other NSAIDs that were included as representative surrogate systems when DCF-specific evidence was unavailable for particular fabrication approaches. The review followed Scale for the Assessment of Narrative Review Articles (SANRA) recommendations. Studies were analyzed using a standardized seven-parameter framework including encapsulation efficiency, release profile, particle size control, polydispersity, scalability, reproducibility, and process complexity. Results: Batch-based techniques, such as thin-film hydration for chitosan-coated liposomal systems, consistently provide high encapsulation efficiency, sustained drug release, and good biocompatibility. However, these methods are often associated with batch-to-batch variability, operator dependence, and limited scalability. In contrast, continuous manufacturing approaches, including microfluidic mixing, nanostructured lipid carriers, and Quality-by-Design (QbD)–guided processes, demonstrate improved control over particle size distribution and polydispersity, enhanced reproducibility, and better scalability potential. Conclusions: Manufacturing methodology is an important determinant of DCF and NSAID nanocarrier performance alongside formulation composition. Continuous manufacturing approaches offer promising improvements in reproducibility, process control, and scalability, but current evidence remains uneven across different nanocarrier classes. Further standardized comparative studies are needed to support their broader translation into clinical applications.